Xtandi (enzalutamide capsules and tablets - Astellas/Pfizer) — Cigna
Prostate Cancer – Non-Metastatic, Castration-Sensitive
Initial criteria
- Patient age ≥ 18 years; AND
- Patient has biochemical recurrence and is at high risk for metastasis.
- Note: High-risk biochemical recurrence is defined as prostate-specific antigen (PSA) doubling time ≤ 9 months.
Approval duration
1 year